TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05160766

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty(BTN162b2)
Description: Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty(BTN162b2)
Description: Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty(BTN162b2)
Description: Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty(BTN162b2)
Description: Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty(BTN162b2)
Description: Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty(BTN162b2)
Description: Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikevax (mRNA-1273)
Description: Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikevax (mRNA-1273)
Description: Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikevax (mRNA-1273)
Description: Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikevax (mRNA-1273)
Description: Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikevax (mRNA-1273)
Description: Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spikevax (mRNA-1273)
Description: Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection
Study: NCT06006026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride 10 MG/ML [Naropin]
Description: According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
Study: NCT05476783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: Clear to slightly opalescent, sterile solution for injection
Study: NCT06654752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Oral Antibiotics
Description: Increase airway clearance and start 14 days of preselected oral antibiotics right away

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
Description: Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria
Study: NCT06284772

Intervention type: OTHER
Intervention: Questionnaire and fecal sampling
Description: The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.

Intervention type: OTHER
Intervention: Questionnaire and fecal sampling
Description: The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.

Intervention type: OTHER
Intervention: Health examination
Description: This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.
Study: NCT06128369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic Suspension
Description: Ophthalmic Suspension,1.5% \[15 mg/mL\] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of OCS-01
Description: inert vehicle of OCS-01 ophthalmic suspension Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
Study: NCT06706219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan plus pembrolizumab
Description: Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.~Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients.
Study: NCT06727383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood collection
Description: standard blood test procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood collection
Description: standard blood test procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Leukapheresis is the procedure that allows the separation and collection of hematopoietic stem cells (HSCs) from peripheral blood. The collection takes place through a machine called a cell separator: it uses centrifugal force to separate the mononuclear cells from all the other cells in the blood and plasma.
Study: NCT06727292

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement
Description: Instant drink in a powder form presented in a sachet to be disolved in a glass of water (200 ml).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Instant drink in powder form in a sachet to be disolved in a glass of water (200ml)
Study: NCT06726213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk and talk
Description: An hour long walk at a slow pace lead by a trained walking leader.
Study: NCT06725940

Intervention type: DEVICE
Intervention: 68Ga-GZMB PET/CT
Description: 68Ga-GZMB PET/CT
Study: NCT05081115

Intervention type: DIAGNOSTIC_TEST
Intervention: ABCDE-Stress Echo
Description: Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.

Intervention type: DIAGNOSTIC_TEST
Intervention: ABCDE-Stress Echo
Description: Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
Study: NCT05080530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Effect of Vitamin D on diabetic neuropathy symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Effect of Vitamin D on diabetic neuropathy symptoms
Study: NCT04833114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mabthera
Description: Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mabthera
Description: Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
Study: NCT01391975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active ultrasound surveillance of fistula and proactive treatment of stenosis
Description: Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
Study: NCT06447090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7; Mitoxantrone Liposomal 30 mg/m2, d1; Cytosine arabinoside(Ara-C) 100 mg/m2/d, d1-7; Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5); After 1 day of rest, cryopreserved donor stem cells MNC1-2X10\^8 /kg infusion, add low-dose (25 mg Bid) and short-course treatment (stop 2-3 weeks after DLI) oral cyclosporine (CSA) to prevent graft-versus-host disease (GVHD) 3 days before cryopreserved stem cell infusion.
Study: NCT05961566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of collagen matrix after subepithelial connective tissue graft harvest
Description: A collagen matrix is placed under the overlying flap after the subepithelial connective tissue graft harvesting.
Study: NCT05938361

Intervention type: OTHER
Intervention: Psoriasis clinical assessments
Description: Global evaluation of psoriasis and specific evaluation by areas

Intervention type: OTHER
Intervention: Quality of life evaluation
Description: DLQI questionnaire at each visit

Intervention type: OTHER
Intervention: Satisfaction assessment
Description: Visual analogic scale at W16, W28, W52

Intervention type: OTHER
Intervention: Pruritus evaluation
Description: Visual analogic scale at each visit
Study: NCT05819164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo oximeter
Description: During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
Study: NCT05081115

Intervention type: DIAGNOSTIC_TEST
Intervention: ABCDE-Stress Echo
Description: Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
Study: NCT05819164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo oximeter
Description: During this period, the Masimo oximeter Radical 7 was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo oximeter
Description: During this period, the Masimo oximeter Radical 7 was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo oximeter
Description: During this period, the Masimo oximeter Radical 7 was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo oximeter
Description: During this period, the Masimo oximeter Radical 7 was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellcor oximeter
Description: During this period, the Nellcor oximeter N-600 was used for SpO2 reading
Study: NCT04833114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
Study: NCT05819164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellcor oximeter
Description: During this period, the Nellcor oximeter N-600 was used for SpO2 reading
Study: NCT04833114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
Study: NCT06508671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DL-3-n-butylphthalide
Description: Take butylphthalide soft capsules orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empty Medication Capsules
Description: Take empty medication capsules orally
Study: NCT05487911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: 4 weeks of active rTMS (total of up to 20 sessions)
Study: NCT06085781

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Pimonidazole
Description: 200 mg and 300 mg tablets

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Pimonidazole
Description: 200 mg and 300 mg tablets
Study: NCT05819164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellcor oximeter
Description: During this period, the Nellcor oximeter N-600 was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellcor oximeter
Description: During this period, the Nellcor oximeter N-600 was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellcor oximeter
Description: During this period, the Nellcor oximeter N-600 was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonin oximeter
Description: During this period, the Nonin oximeter was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonin oximeter
Description: During this period, the Nonin oximeter was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonin oximeter
Description: During this period, the Nonin oximeter was used for SpO2 reading
Study: NCT05819164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonin oximeter
Description: During this period, the Nonin oximeter was used for SpO2 reading

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonin oximeter
Description: During this period, the Nonin oximeter was used for SpO2 reading
Study: NCT05157932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talk test prescription
Description: Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on the Talk test method.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPET prescription
Description: Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on their CPET results completed at baseline
Study: NCT04971486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Sequence Task
Description: Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Sequence Task
Description: Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear.
Study: NCT06249087

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study: NCT05369351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment+mirabegron
Description: In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: Standard treatment
Study: NCT05551143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LiftKit
Description: The LiftKit contains 7 tools that could assist EMS providers when lifting/moving patients. These tools are:~1. Simple Strap - A sling to lift a seated patient~2. Strap and slide stick - A strap system for raising a supine patient to a sitting posture.~3. Slip Preventer- An envelope that goes over the patients feet with high friction straps for the EMS providers to stand on that prevent the patient from sliding forward when lifted.~4. Drag Straps - straps with handles that can be clipped on tarps used to drag patients~5. The Binder Lift - a vest with handles that allow EMS providers to easily get hold of patient they need to lift.~6. Patient Turning Straps - a way to log-roll a patient that in on the floor while in a standing posture.~7. The ELK - an inflatable seat cushion that can raise a patient who in the floor to chair level
Study: NCT05333861

Intervention type: DRUG
Intervention: hetrombopag
Description: According to prescription